Non Small Cell Lung Cancer - Immunotherapy - HLA-A underexpression + PD-L1 expression

Association details:

Biomarker:	HLA-A underexpression + PD-L1 expression
Cancer:	Non Small Cell Lung Cancer
Drug Class:	Immunotherapy
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

ELCC 2023

Title:

9MO - Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer

Published date:

03/23/2023

Excerpt:

Here we evaluate HLA-1 and other immune-related markers as potential predictive factors of response to ICI in NSCLC….Our work reveals that ∼45% of NSCLC in our cohort express low staining levels of HLA-1 (down regulation or total absence) compared to normal/high staining (55%). Those patients present worse clinical outcomes: mPFS to IT 9.1 (6.5–20.2) vs 21 (13.9-NR) months (p-value 0.028), respectively. We also report that HLA-1 is co-expressed with PD-L1 (p <0.005), regardless of histological subtype.